Market Place
Sourcing Support
Ignite Proteomics To Present MHC-II Data On Pembrolizumab Response
24 Feb 2025 //
GLOBENEWSWIRE
Ignite Proteomics Acquires PLA Code 0249U for Breast Cancer Assay
19 Feb 2025 //
GLOBENEWSWIRE
Ignite Proteomics Publishes Study on Activation in Breast Cancer
10 Feb 2025 //
GLOBENEWSWIRE
IMAC Ignite Proteomics Matches Patients With Cancer Therapies
27 Jan 2025 //
GLOBENEWSWIRE
IMAC Holdings Receives Deficiency Notice From Nasdaq For Late Filing
22 Nov 2024 //
GLOBENEWSWIRE
IMAC Holdings Regains Compliance with Nasdaq Listing Rule 5250
14 Nov 2024 //
GLOBENEWSWIRE
IMAC Holdings Launches Ignite Proteomics With Case Study
19 Sep 2024 //
GLOBENEWSWIRE
IMAC Holdings Receives Nasdaq Deficiency Notice For Delayed 10-Q Filing
23 Aug 2024 //
GLOBENEWSWIRE
IMAC Holdings Appoints Two New Directors To Board
11 Jul 2024 //
GLOBENEWSWIRE
IMAC Holdings Announces Leadership Succession
24 May 2024 //
GLOBENEWSWIRE
IMAC Holdings Acquires Theralink Assets For Precision Medicine Business
07 May 2024 //
GLOBENEWSWIRE
IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
27 Sep 2023 //
GLOBENEWSWIRE
IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split
07 Sep 2023 //
GLOBENEWSWIRE
IMAC Holdings Announces $4.3M Private Placement of Convertible Preferred Stock
26 Jul 2023 //
GLOBENEWSWIRE
IMAC Holdings Annual Meeting of Shareholders Reminder
28 Jun 2023 //
GLOBENEWSWIRE
Theralink Signs Definitive Merger Agreement to be Acquired by IMAC Holdings
23 May 2023 //
GLOBENEWSWIRE
IMAC Holdings Reports Year End 2022 Financial Results and Corporate Update
31 Mar 2023 //
GLOBENEWSWIRE
IMAC Holdings and Brain Scientific Announce a Strategic Merger
20 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.